Treatment of Breast and Prostate Cancer by Hypofractionated Radiotherapy: Potential Risks and Benefits

Noldus, 2000, Stage migration in clinically localized prostate cancer, Eur Urol, 38, 74, 10.1159/000020255

Withers, 1992, Biological basis of radiation therapy for cancer, Lancet, 339, 156, 10.1016/0140-6736(92)90218-R

Zaorsky, 2013, Systematic review of hypofractionated radiation therapy for prostate cancer, Cancer Treat Rev, 39, 728, 10.1016/j.ctrv.2013.01.008

Barnett, 2009, Normal tissue reactions to radiotherapy: towards tailoring treatment dose by genotype, Nature Rev Cancer, 9, 134, 10.1038/nrc2587

Stone, 2003, Effects of radiation on normal tissue: consequences and mechanisms, Lancet Oncol, 4, 529, 10.1016/S1470-2045(03)01191-4

Ritter, 2008, Rationale, conduct, and outcome using hypofractionated radiotherapy in prostate cancer, Semin Radiat Oncol, 18, 249, 10.1016/j.semradonc.2008.04.007

Williams, 1985, A review of alpha/beta ratios for experimental tumors: implications for clinical studies of altered fractionation, Int J Radiat Oncol Biol Phys, 11, 87, 10.1016/0360-3016(85)90366-9

Barendsen, 1982, Dose fractionation, dose rate and iso-effect relationships for normal tissue responses, Int J Radiat Oncol Biol Phys, 8, 1981, 10.1016/0360-3016(82)90459-X

Barton, 1995, Tables of equivalent dose in 2 Gy fractions: a simple application of the linear quadratic formula, Int J Radiat Oncol Biol Phys, 31, 371, 10.1016/0360-3016(94)E0126-5

Horiot, 1992, Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma: final analysis of a randomized trial of the EORTC cooperative group of radiotherapy, Radiother Oncol, 25, 231, 10.1016/0167-8140(92)90242-M

Brenner, 2002, Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio), similar to late-responding normal tissue, Int J Radiat Oncol Biol Phys, 52, 6, 10.1016/S0360-3016(01)02664-5

Whelan, 2008, Clinical experience using hypofractionated radiation schedules in breast cancer, Semin Radiat Oncol, 18, 257, 10.1016/j.semradonc.2008.04.008

Haustermans, 1997, Cell kinetic measurements in prostate cancer, Int J Radiat Oncol Biol Phys, 37, 1067, 10.1016/S0360-3016(96)00579-2

Pollack, 1994, Prostate specific antigen doubling time and disease relapse after radiotherapy for prostate cancer, Cancer, 74, 670, 10.1002/1097-0142(19940715)74:2<670::AID-CNCR2820740220>3.0.CO;2-8

Rew, 2000, Cell production rates in human tissues and tumours and their significance. Part II: clinical data, Eur J Surg Oncol, 26, 405, 10.1053/ejso.1999.0907

Parthan, 2012, Comparative cost-effectiveness of stereotactic body radiation therapy versus intensity-modulated and proton radiation therapy for localized prostate cancer, Frontiers Oncol, 2, 81, 10.3389/fonc.2012.00081

Sethukavalan, 2012, Patient costs associated with external beam radiotherapy treatment for localized prostate cancer: the benefits of hypofractionated over conventionally fractionated radiotherapy, Can J Urol, 19, 6165

Whelan, 2010, Long-term results of hypofractionated radiation therapy for breast cancer, New Engl J Med, 362, 513, 10.1056/NEJMoa0906260

Haviland, 2013, The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials, Lancet Oncol, 14, 1086, 10.1016/S1470-2045(13)70386-3

Agrawal, 2011, First results of the randomised UK FAST Trial of radiotherapy hypofractionation for treatment of early breast cancer (CRUKE/04/015), Radiother Oncol, 100, 93, 10.1016/j.radonc.2011.06.026

Coles, 2013, Breast radiotherapy: less is more?, Clin Oncol, 25, 127, 10.1016/j.clon.2012.10.013

Yeoh, 2011, Hypofractionated versus conventionally fractionated radiotherapy for prostate carcinoma: final results of phase III randomized trial, Int J Radiat Oncol Biol Phys, 81, 1271, 10.1016/j.ijrobp.2010.07.1984

Miralbell, 2012, Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5,969 patients in seven international institutional datasets: alpha/beta = 1.4 (0.9-2.2) Gy, Int J Radiat Oncol Biol Phys, 82, e17, 10.1016/j.ijrobp.2010.10.075

Dearnaley, 2012, Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial, Lancet Oncol, 13, 43, 10.1016/S1470-2045(11)70293-5

Olivotto, 2013, Interim cosmetic and toxicity results from RAPID: a randomized trial of accelerated partial breast irradiation using three-dimensional conformal external beam radiation therapy, J Clin Oncol, 31, 4038, 10.1200/JCO.2013.50.5511

Fowler, 2001, Is alpha/beta for prostate tumors really low?, Int J Radiat Oncol Biol Phys, 50, 1021, 10.1016/S0360-3016(01)01607-8

Fowler, 2006, Point/Counterpoint. The best radiotherapy for the treatment of prostate cancer involves hypofractionation, Med Phys, 33, 3081, 10.1118/1.2179008

Arcangeli, 2010, A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high-risk prostate cancer, Int J Radiat Oncol Biol Phys, 78, 11, 10.1016/j.ijrobp.2009.07.1691

Pollack, 2013, Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer, J Clin Oncol, 31, 3860, 10.1200/JCO.2013.51.1972

Kirkpatrick, 2008, The linear-quadratic model is inappropriate to model high dose per fraction effects in radiosurgery, Semin Radiat Oncol, 18, 240, 10.1016/j.semradonc.2008.04.005

Courdi, 2010, High doses per fraction and the linear-quadratic model, Radiother Oncol, 94, 121, 10.1016/j.radonc.2009.08.019

Otsuka, 2011, Compatibility of the linear-quadratic formalism and biologically effective dose concept to high-dose-per-fraction irradiation in a murine tumor, Int J Radiat Oncol Biol Phys, 81, 1538, 10.1016/j.ijrobp.2011.05.034

Lennernas, 2011, Hypofractionation for radiotherapy of prostate cancer using a low alfa/beta ratio–possible reasons for concerns? An example of five dimensional radiotherapy, Acta Oncol, 50, 111, 10.3109/0284186X.2011.562536

Bloom, 1957, Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years, Br J Cancer, 11, 359, 10.1038/bjc.1957.43

Burrell, 2013, The causes and consequences of genetic heterogeneity in cancer evolution, Nature, 501, 338, 10.1038/nature12625

Aihara, 1994, Prostate specific antigen and Gleason grade: an immunohistochemical study of prostate cancer, J Urol, 151, 1558

Carlson, 2011, Hypofractionation results in reduced tumor cell kill compared to conventional fractionation for tumors with regions of hypoxia, Int J Radiat Oncol Biol Phys, 79, 1188, 10.1016/j.ijrobp.2010.10.007

Kal, 2003, How low is the alpha/beta ratio for prostate cancer?, Int J Radiat Oncol Biol Phys, 57, 1116, 10.1016/S0360-3016(03)01455-X

Oliveira, 2012, What do we know about the alpha/beta for prostate cancer?, Med Phys, 39, 3189, 10.1118/1.4712224

Ghilezan, 2010, Adaptive radiation therapy for prostate cancer, Semin Radiat Oncol, 20, 130, 10.1016/j.semradonc.2009.11.007